Related references
Note: Only part of the references are listed.Linkage-specific ubiquitin chain formation depends on a lysine hydrocarbon ruler
Joanna Liwocha et al.
NATURE CHEMICAL BIOLOGY (2021)
Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation
TaeJin Lee et al.
ORGANIC LETTERS (2020)
Antibody-Drug Conjugates: The Last Decade
Nicolas Joubert et al.
PHARMACEUTICALS (2020)
Sulfatase-cleavable linkers for antibody-drug conjugates
Jonathan D. Bargh et al.
CHEMICAL SCIENCE (2020)
AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies
Kei Yamada et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Site-Specific Chemical Conjugation of Antibodies by Using Affinity Peptide for the Development of Therapeutic Antibody Format
Satoshi Kishimoto et al.
BIOCONJUGATE CHEMISTRY (2019)
Development, Optimization, and Structural Characterization of an Efficient Peptide-Based Photoaffinity Cross-Linking Reaction for Generation of Homogeneous Conjugates from Wild-Type Antibodies
Nicholas Vance et al.
BIOCONJUGATE CHEMISTRY (2019)
Peptide-Directed Photo-Cross-Linking for Site-Specific Conjugation of IgG
Jisoo Park et al.
BIOCONJUGATE CHEMISTRY (2018)
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Nirnoy Dan et al.
PHARMACEUTICALS (2018)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Exploring chemoselective S-to-N acyl transfer reactions in synthesis and chemical biology
Helen M. Burke et al.
NATURE COMMUNICATIONS (2017)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
Site-Specific Antibody-Drug Conjugates: The Nexus of Biciorthogonal Chemistry, Protein Engineering, and Drug Development
Paresh Agarwal et al.
BIOCONJUGATE CHEMISTRY (2015)
Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy
Ravi V. J. Chari et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
John M. Lambert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Antibody-drug conjugates: Basic concepts, examples and future perspectives
Giulio Casi et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen et al.
NATURE BIOTECHNOLOGY (2012)
Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma
Sungwook Choi et al.
NATURE CHEMICAL BIOLOGY (2010)
Tetrazine-Based Cycloadditions: Application to Pretargeted Live Cell Imaging
Neal K. Devaraj et al.
BIOCONJUGATE CHEMISTRY (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
HER2 therapy - Molecular mechanisms of trastuzumab resistance
Rita Nahta et al.
BREAST CANCER RESEARCH (2006)
Structural characterization of the maytansinoid -: monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry
LT Wang et al.
PROTEIN SCIENCE (2005)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex:: Mechanism of pH-dependent binding
WL Martin et al.
MOLECULAR CELL (2001)
A traceless Staudinger ligation for the chemoselective synthesis of amide bonds
E Saxon et al.
ORGANIC LETTERS (2000)
Share Paper
